Belsomra vs Trazodone: Titration Speed and Tolerability Compared

How Each Drug Works and Why It Matters for Titration

Suvorexant and trazodone reach the same clinical endpoint, less broken sleep, but by completely different mechanisms. That difference shapes how fast a prescriber can push the dose and how much tolerance the patient needs to develop before the drug feels comfortable.

Suvorexant: Blocking the Wake Signal

Suvorexant blocks both orexin-1 and orexin-2 receptors in the lateral hypothalamus. Orexin (also called hypocretin) is the neurochemical that keeps the brain awake. By occupying those receptors, suvorexant does not sedate in the traditional sense. It simply removes the physiological instruction to stay awake. Because the mechanism is narrow and targeted, the drug has a predictable on/off profile and does not require gradual dose escalation to allow receptor adaptation. The FDA-approved dose range is 10 mg to 20 mg, and the entire titration is one optional upward step.

Trazodone: Sedation Through Receptor Antagonism at Low Doses

Trazodone is an antidepressant at doses of 150 to 600 mg per day, where its serotonin reuptake inhibition becomes relevant. At hypnotic doses of 25 to 150 mg, its sedative effect comes primarily from histamine H1 and alpha-1 adrenergic receptor antagonism. [1] That combination explains both its usefulness and its tolerability problems. Histamine blockade causes sedation but also morning grogginess; alpha-1 blockade lowers blood pressure and can cause dizziness, particularly dangerous in older adults. These receptor effects require the prescriber to escalate the dose slowly, watching for blood pressure drops and daytime carry-over before each upward step.

Titration Protocols: Step by Step

Suvorexant Titration

The FDA label for suvorexant (Belsomra) specifies a single starting dose of 10 mg taken no more than 30 minutes before bedtime, with at least 7 hours remaining before the planned wake time. [2] If 10 mg is tolerated but insufficient after several nights, the prescriber may increase to 20 mg. That is the maximum approved dose. No further titration exists. The entire process can be completed in under two weeks, and many patients stay at 10 mg indefinitely.

Patients over 65 do not require an automatic dose reduction, but the FDA recommends starting at 10 mg and being cautious about the 20 mg step because of modestly higher plasma exposure in older adults. Hepatic impairment does not require adjustment at 10 mg; severe hepatic impairment is a contraindication to the higher dose.

Trazodone Titration for Insomnia

Trazodone carries no FDA-approved insomnia indication, so all dosing is off-label and derived from clinical practice guidelines rather than a package insert. Typical practice starts at 25 to 50 mg at bedtime. The prescriber then reassesses every one to two weeks. If the patient tolerates the starting dose without problematic morning sedation or orthostatic symptoms, the dose may be raised by 25 to 50 mg increments. Most insomnia patients achieve adequate response between 50 mg and 100 mg; a small number require 150 mg. [3]

Because of the alpha-1 blockade, each upward step carries a real risk of falls in older adults. A 2005 review by Mendelson published in the Journal of Clinical Psychiatry noted that trazodone's hypnotic effect at low doses is "largely a function of its antihistaminic and alpha-adrenergic blocking properties" and that these same properties account for its most frequent adverse effects at sleep doses. [3] A prescriber working with a 70-year-old patient may spend six to eight weeks titrating carefully, a timeline that stands in sharp contrast to suvorexant's one-step approach.

Efficacy Data: What the Trials Actually Showed

Suvorexant Phase 3 Evidence

The key evidence for suvorexant comes from Herring et al. (The Lancet Neurology, 2012, published 2014), two randomized, double-blind, placebo-controlled trials (N=1,021 combined) in adults with primary insomnia. [4] At the 20 mg dose in adults under 65, the drug reduced subjective sleep onset latency by 9 minutes versus placebo and reduced wake after sleep onset (WASO) by 28 minutes at month 3. Objective polysomnography confirmed these findings. Critically, the benefit was measurable on night 1, which means titration does not delay the therapeutic response. Patients do not have to wait weeks to know whether the drug is working.

The 2014 Herring trial also reported that the 10 mg dose in adults over 65 reduced WASO by approximately 21 minutes versus placebo at month 3, with an acceptable safety profile. [4]

Trazodone Efficacy at Hypnotic Doses

Trazodone's insomnia evidence base is considerably thinner. Most published trials are small, short, and enrolled patients with comorbid depression rather than primary insomnia. A widely cited 1994 trial (Walsh et al., N=35) showed trazodone 50 mg improved total sleep time by about 37 minutes over placebo in the first week. By week two, however, the effect was not statistically significant, raising questions about rapid tolerance at the low hypnotic dose. [5]

Mendelson's 2005 review concluded that while trazodone's short-term sleep benefits are real, "evidence for efficacy beyond 2 weeks is limited," and that its widespread off-label use for insomnia has substantially outpaced the evidence supporting it. [3] This matters clinically: a prescriber spending several weeks carefully titrating trazodone may be investing time in a drug whose efficacy may be waning by the time the optimal dose is reached.

Tolerability: Where the Drugs Differ Most

Suvorexant Tolerability Profile

The most common adverse effect in suvorexant trials was somnolence, reported in 7% of patients at 20 mg versus 3% for placebo in the Herring studies. [4] Next-day impairment at 20 mg was measurable on driving simulation tests, which is why the FDA label warns against driving the morning after taking 20 mg until the individual patient knows how the drug affects them.

Rare but notable adverse effects include sleep paralysis (reported in 0.9 to 1.4% of patients), hypnagogic or hypnopompic hallucinations (0.4 to 1%), and cataplexy-like events. These events emerge from the orexin-blocking mechanism itself and do not necessarily resolve with dose reduction. Patients with narcolepsy should not take suvorexant. The drug is not habit-forming in the clinical sense that benzodiazepines are, but it carries DEA Schedule IV status, meaning prescribers must follow controlled-substance rules.

Trazodone Tolerability Profile

Trazodone's tolerability issues are largely predictable from its receptor pharmacology. Orthostatic hypotension is the most clinically serious concern in older adults. A meta-analysis of trazodone adverse events found that dizziness and hypotension occurred in roughly 5 to 10% of patients taking low-dose trazodone for sleep, with rates higher in those over 65 or taking antihypertensives. [5]

Morning sedation and "hangover" are common complaints, particularly during the titration phase when the dose is being adjusted. This occurs because trazodone's half-life of 5 to 9 hours can overlap significantly with the waking period if the patient takes the drug later in the night or if the dose is higher than necessary.

Priapism is rare (estimated at 1 in 6,000 male patients in prescribing literature) but constitutes a urological emergency and requires immediate discontinuation. [6] Cardiac arrhythmia risk is low at hypnotic doses but real in overdose scenarios or in patients with pre-existing QT prolongation.

Drug-drug interactions also differ between the two agents. Trazodone's serotonin activity creates serotonin syndrome risk when combined with MAOIs, SSRIs at higher doses, or tramadol. Suvorexant interacts primarily with CYP3A4 inhibitors (e.g., ketoconazole), which can double plasma levels and require dose reduction to 5 mg.

Switching from Belsomra to Trazodone: Clinical Considerations

Patients switch from suvorexant to trazodone for several reasons: cost (trazodone is generic and often under $10 per month), a desire to avoid a scheduled substance, or the presence of comorbid depression or anxiety where trazodone's antidepressant mechanism at higher doses could serve dual purposes.

The switch does not require a washout period. Suvorexant's half-life is approximately 12 hours, so clinically relevant plasma levels clear within two to three days of the last dose. A prescriber can stop suvorexant on day 1 and start trazodone 50 mg on the same night, then titrate upward over subsequent weeks.

The Titration Gap During Switching

The practical problem is the efficacy gap during trazodone titration. A patient who has been sleeping adequately on suvorexant 20 mg may experience a rough two to four weeks while trazodone is being built up to its effective dose. Prescribers should warn patients explicitly about this. Non-pharmacological strategies such as stimulus control, sleep restriction, and relaxation techniques from cognitive behavioral therapy for insomnia (CBT-I) can bridge the gap and are recommended by the American Academy of Sleep Medicine as first-line therapy regardless of which drug is being used. [7]

When the Switch Is Not Advisable

Switching to trazodone is generally not advisable in the following situations:

• The patient is over 65 with a fall history or takes antihypertensive medications, because of orthostatic hypotension risk.
• The patient has a history of priapism or prolonged erection with any medication.
• The patient is already on an SSRI, SNRI, or other serotonergic agent, where the combination raises serotonin syndrome risk.
• The patient's insomnia is exclusively sleep-onset insomnia without any mood component, because trazodone's evidence for pure sleep-onset insomnia is weaker than suvorexant's Phase 3 data.

When the Switch Makes Sense

Trazodone becomes a reasonable first or second choice when the patient has comorbid major depressive disorder being managed by a psychiatrist, is cost-constrained with no insurance coverage for brand-name or generic suvorexant, or when the prescriber and patient prefer a non-scheduled agent for logistical reasons. The 2017 American College of Physicians guideline on chronic insomnia treatment also notes that off-label sedating antidepressants like trazodone "may be reasonable" in patients with comorbid mood disorders, though the evidence grade remains low. [7]

Special Populations: Older Adults and Patients with Comorbidities

Older Adults

Both drugs carry caution labels for older adults, but for different reasons and of different magnitudes. The Beers Criteria (2023 update from the American Geriatrics Society) does not list suvorexant among drugs to avoid in older adults, representing a meaningful departure from benzodiazepines and non-benzodiazepine hypnotics like zolpidem. [8] Trazodone, by contrast, appears on the Beers list as potentially inappropriate in older adults due to orthostatic hypotension and the associated fall and fracture risk.

A patient aged 72 with primary insomnia and no mood disorder is a much better candidate for carefully titrated suvorexant than for trazodone, at least from a falls perspective.

Patients with Depression

A patient with both insomnia and major depressive disorder presents differently. Trazodone at antidepressant doses (150 to 400 mg) may address both conditions. In this scenario, the sleep benefit is a secondary gain from a medication the patient may need regardless. Suvorexant does not treat depression and should not be selected on the assumption that sleep improvement will resolve depressive symptoms.

Patients with Substance Use History

Suvorexant's Schedule IV status means it requires a written or electronic controlled-substance prescription and in some states mandates prescription drug monitoring program (PDMP) queries. This is not merely administrative. In patients with a history of alcohol or sedative misuse, a non-scheduled agent like trazodone may be a deliberate clinical preference, even if the evidence for trazodone is thinner. The 2023 AASM position paper on hypnotics notes that abuse potential for suvorexant appears low in clinical studies but acknowledges that real-world data in high-risk populations remain limited. [9]

Comparing Titration Speed Side by Side

The clearest way to see the practical difference is to lay out the week-by-week trajectory for each drug in a typical adult patient with primary insomnia and no psychiatric comorbidity.

| Week | Suvorexant | Trazodone | |---|---|---| | Week 1 | Start 10 mg. Measurable effect expected night 1 to night 3. | Start 25 to 50 mg. Partial effect. Monitor for morning dizziness. | | Week 2 | Assess: if 10 mg sufficient, stop here. If insufficient, increase to 20 mg. | Reassess tolerance. Increase to 50 to 75 mg if tolerated. | | Week 3 to 4 | Stable at 10 or 20 mg. No further changes needed. | Further increase to 75 to 100 mg if needed. Watch orthostatic BP. | | Week 5 to 6 | No changes. Follow-up in 4 to 8 weeks. | Final dose assessment. Maximum hypnotic dose ~100 to 150 mg. |

The table above shows that suvorexant reaches its clinical steady state by week 2. Trazodone may require four to six weeks of active titration before the prescriber and patient are confident the right dose has been found. That is not a disqualifying disadvantage, but it is a real one that matters when a patient is in acute distress from poor sleep.

Cost, Access, and Practical Prescribing

Cost is not a trivial consideration. Generic suvorexant became available in the United States in late 2023 after the patent on Belsomra expired. Even so, generic suvorexant typically costs $30, $80 per month without insurance, compared with $5, $12 per month for generic trazodone. For uninsured or underinsured patients, that difference is decisive.

Prior authorization requirements for suvorexant remain common under Medicare and many commercial plans. A prescriber choosing suvorexant should anticipate a prior-authorization workflow that can delay the first prescription by three to seven days. Trazodone requires no prior authorization under any major formulary reviewed as of 2024.

Prescribers using suvorexant must comply with Schedule IV requirements in their state, including PDMP checks in the majority of US states that mandate them for controlled substances. Trazodone requires no such steps.